Watch the webcasts from our industry partners' Satellite Symposia.
13/09/2024
Bristol Myers Squibb:
Therapeutic Advances in GI Cancers: Immuno-Oncology and Beyond
- Welcome and Introduction
Sara Lonardi - Colorectal Cancer: Novel Combination Therapies
Sara Lonardi - Gastroesophageal Cancers: the Role of Immunotherapy
Tania Fleitas - Hepatocellular Carcinoma: First-line Treatment Options in the Metastatic Setting
Thomas Decaens - Summary and Close
Sara Lonardi
Johnson & Johnson:
Optimising the personalisation of GU cancer care
Coming soon
- Welcome and Introduction
Patrizia Giannatempo, Alison Birtle - Unveiling real-world evidence: Exploring the PSA Response in mHSPC
Alison Birtle - Efficacy and QoL in mHSPC – finding the right balance
Alejo Rodriguez-Vida - The significance of BRCA1/2 mutations in mCRPC outcomes
Elena Verzoni - Panel discussion
Patrizia Giannatempo, Alison Birtle, Alejo Rodriguez-Vida, ElenaVerzoni - The evolving patient pathway in mUC: What do the changing guidelines mean for treatment sequencing?
Simon Crabb - FGFR testing: Why, how, when?
Viktor Gruenwald - Optimising patient care: Managing adverse events
Simon Crabb, Viktor Gruenwald - Summary and Close
Patrizia Giannatempo, Alison Birtle
Johnson & Johnson and Thermo Fisher Scientific:
Maximising the synergy of tumour tissue and liquid biopsy testing in oncology clinical practice
Coming soon
- The state of the art of liquid biopsy for solid tumour molecular testing
Christian Rolfo - Molecular testing in GU oncology: Addressing challenges and unmet needs
Guilhem Roubaud - Molecular testing in NSCLC: The role of liquid biopsy
Federico Cappuzzo - Q&A - Oncologist perspective
Christian Rolfo, Guilhem Roubaud, Federico Cappuzzo, Sara Pilotto, Bence Sipos - Practical insights on NGS implementation in clinical routine
Bence Sipos - Navigating real-world challenges: Case studies in oncology practice
Sara Pilotto - Conclusion
Christian Rolfo
Pfizer Oncology:
Breaking new ground: PARPi + ARPi combination therapy in mCRPC
- Welcome and Introductions
Neal Shore - Beyond BRCA: examining the evidence for novel PARPi combinations in mCRPC
Axel Merseburger - Harnessing the potential of HRR gene profiling to inform treatment decisions
Eleni Efstathiou - Patient-centered approaches - who should we treat with PARPi and how?
Neal Shore, Axel Merseburger, Eleni Efstathiou - Q&A
Neal Shore, Axel Merseburger, Eleni Efstathiou - Conclusion
Neal Shore
Servier:
Advancements in Metastatic Pancreatic Cancer: Which perspectives for patients?
- Introduction
Eric Van Cutsem - Navigating the latest news and guidelines in Metastatic Pancreatic Cancer
Gerald Prager - Integrating new data into current clinical practice: Key learnings from Napoli 3 study
Teresa Macarulla Mercade - Focusing on long term benefits: insights from NALLONG study
Jean-Luc van Laethem - Exploring Recent Clinical Data: Perspectives from the Japanese Experience
Masafumi Ikeda - Panel discussion
Eric Van Cutsem, Teresa Macarulla Mercade, Gerald Prager, Jean-Luc van Laethem, Masafumi Ikeda - Conclusion
Teresa Macarulla Mercade
Servier:
Precision Medicine: From Early Detection to Improved Outcomes in Patients with IDH Mutations
- Role of IDH mutations in cancers
John Bridgewater - IDH: A common mutation in a rare cancer: Focus on Glioma
Ghazaleh Tabatabai - IDH: A common mutation in a rare cancer: Focus on Chondrosarcoma
Silvia Stacchiotti - IDH: A rare mutation in common cancers: Focus on AML and CCA
Teresa Macarulla Mercade - Panel Discussion
John Bridgewater, Teresa Macarulla Mercade, Ghazaleh Tabatabai, Silvia Stacchiotti - Conclusion
Teresa Macarulla Mercade
14/09/2024
Bristol Myers Squibb:
A decade of anti–PD-1–based therapies for melanoma: looking beyond the curves
Coming soon
- Welcome and introduction
Eva Muñoz Couselo - The past, present, and future for melanoma therapy
Michael Postow - 2024 treatment in focus: immuno-oncology for the neoadjuvant/perioperative setting
Christoph Hoeller - Navigating treatment in the neoadjuvant/perioperative setting: an interactive conversation
Eva Muñoz Couselo, Michael Postow, Christoph Hoeller - Summary and close
Eva Muñoz Couselo
Bristol Myers Squibb:
Evolving Patient-Centered Therapies for Metastatic NSCLC
- Welcome and Introduction
Jarushka Naidoo - The Importance of Patient Empowerment During Their Journey
Terri Conneran - PD-L1 <1% in Metastatic NSCLC: Guiding Treatment Decisions for Potential Durable Outcomes in a Patient Population With Unmet Needs
Luis Paz-Ares - Kicking Off Targeted Medicine for Patients With KRAS G12C–Mutated Metastatic NSCLC
Jarushka Naidoo - Next-Generation Tyrosine Kinase Inhibitors: The Evolving Treatment Landscape of Cancers With ROS1 or NTRK Fusions
Alexander Drilon - Panel Discussion: What Would Be Your Treatment Decision?
Jarushka Naidoo, Luis Paz-Ares, Terri Conneran, Alexander Drilon - Closing Remarks
Jarushka Naidoo
Eisai Inc.:
Evolving Treatment Sequence for Renal Cell Carcinoma
- Welcome and Introduction
Toni Choueiri - aRCC 1L treatment selection
Brian Rini - Managing response to IO-TKI combinations in 1L RCC
Viktor Gruenwald - New perspectives in the post IO setting
Manuela Schmidinger - Round table case discussions, Q&A
Toni Choueiri - Summary and key takeaways
Manuela Schmidinger
Ipsen:
Kidney cancer puzzles – from insights to progress
- Welcome and Introduction
Laurence Albiges - The adjuvant puzzle: how do we pick the right patient?
Jens Bedke - How can you select the best 1L option for your patient?
Sumanta Pal, Laurence Albiges - How can we simplify sequencing?
Guillermo Antonio De Velasco Oria - Burning questions: what riddles remain?
Laurence Albiges, Jens Bedke, Guillermo Antonio De Velasco Oria, Sumanta Pal - Closing Remarks
Laurence Albiges
Servier:
Optimizing the continuum of care for Metastatic Colorectal Cancer patients in 3L setting and beyond
- Introduction
Michel Ducreux - Navigating the current treatment landscape in 3L mCRC and beyond
Chiara Cremolini - Evolving strategies in 3L mCRC treatment
Lukas Weiss - Patient cases: clinical insights and treatment options in 3rd and beyond
Kathrin Heinrich - Panel discussion: Insights from experts’ perspectives on future therapies in colorectal cancer management
Michel Ducreux, Lukas Weiss, Chiara Cremolini, Kathrin Heinrich - Conclusion
Lukas Weiss
15/09/2024
Bayer:
Managing menopausal symptoms in patients undergoing endocrine therapy due to hormone-receptor positive breast cancer
- Welcome and introduction: Addressing menopause symptoms following treatment for breast cancer
Sibylle Loibl - The burden of induced menopause symptoms on women’s health
Marion Kiechle - KNDy neurons and science behind menopause
Victor Navarro - Options for symptoms management and unmet needs
Donal Brennan - Round table discussion and Q&A
Sibylle Loibl, Marion Kiechle, Victor Navarro, Donal Brennan - Close
Sibylle Loibl
Boehringer Ingelheim:
Emerging therapies in clinical practice: What are the patient perspectives on the future of lung cancer treatment?
Coming soon
- Welcome & Introducion
Martin Wermke - Unmet needs and future perspectives for treatment of lung cancer
Gerrina Ruiter - Emerging targeted therapies in lung cancers of neuroendocrine origin: DLL3
Martin Wermke - Selectively targeting HER2 in NSCLC
Jon Zugazagoitia - Panel discussion and audience Q&A
Martin Wermke, Gerrina Ruiter, Jon Zugazagoitia - Chair’s closing remarks
Martin Wermke
Bristol Myers Squibb:
Developments in Genitourinary Cancer Management: Joint Decision Making in MIUC and Advanced RCC
- Welcome and Introduction
Michael Jewett - Clinical Considerations in Early Stages of Cancer: the MIUC Experience
Andrea Necchi - Role of Long-term Efficacy, Safety Outcomes and Different Routes of Administration in the Advance Disease Setting: the RCC Experience
Laurence Albiges - Improving Joint Decision Making in Genitourinary Cancers
Michael Jewett - Q&A Session
Michael Jewett, Andrea Necchi, Laurence Albiges - Closing Remarks
Laurence Albiges
Illumina:
Liquid biopsy-based biomarkers for cancer profiling and monitoring: current and future applications
- Welcome
Umberto Malapelle - Introduction to the value of liquid biopsy testing in oncology
Umberto Malapelle - National implementation of Liquid Biopsy testing for Non Small Cell Lung Cancer – QuicDNA
Magdalena Meissner - Added value of Liquid Biopsy testing in advanced cancer – IMPRESS NORWAY
Åslaug Helland - The Value of Liquid Biopsy Testing in Colorectal Cancer: The Patient Advocacy Perspective
Stephen Rowley - Panel discussion
Umberto Malapelle, Magdalena Meissner, Åslaug Helland, Stephen Rowley
Johnson & Johnson:
Driving EGFR-mutant NSCLC care forward
- Welcome and introductions
Noemi Reguart Aransay - A new era for treatment-naïve patients with common EGFR mutations
Alexander Spira - Breaking barriers upon EGFR treatment resistance
Sanjay Popat - Discussion
Noemi Reguart Aransay, Antonio Passaro, Sanjay Popat, Alexander Spira, Enriqueta Felip - The evolving management of patients with EGFR exon20insertion mutations
Enriqueta Felip - Discussion
Noemi Reguart Aransay, Antonio Passaro, Sanjay Popat, Alexander Spira, Enriqueta Felip - Closing remarks
Antonio Passaro
Pfizer Oncology:
Setting a new benchmark for ALK+ aNSCLC targeted therapy
- Welcome and introduction
Tony S.K. Mok - Latest data in the 1L ALK+ aNSCLC treatment landscape
Justin Gainor - Optimising 1L treatment in clinical practice
Tony S.K. Mok - Practical strategies for managing adverse events
Enriqueta Felip - ALK+ aNSCLC treatment expectations now and in the future
Tony S.K. Mok - Meeting close
Tony S.K. Mok
16/09/2024
BeiGene:
A new comprehensive approach to lung cancer treatment
Coming soon
- Welcome and Introduction
Silvia Novello - Resectable NSCLC – neo-adjuvant/adjuvant
Mariano Provencio Pulla - Single agent IO is the only treatment option for NSCLC with PD-L1 high expression (debate: PRO – M. Reck; CON – T. Mok)
Tony S.K. Mok, Martin Reck - What to do in NSCLC with low PD-L1 expression?
Luis Paz-Ares - 1L SCLC
Silvia Novello - General panel discussion / audience Q&A
Silvia Novello, Mariano Provencio Pulla, Tony S.K. Mok, Martin Reck, Luis Paz-Ares - Take-home messages and farewell
Tony S.K. Mok